This trial is completed!
Search for a recruiting clinical trial for your condition
You can access this
clinical trial
if you have
Anemia, Primary Myelofibrosis or Secondary Myelofibrosis
and you are
over 18
years old
Phase
2
This is a second phase trial assessing
efficacy and side effects of the new treatment.
Show me locations

The purpose

This phase II pilot trial studies how well ruxolitinib phosphate and danazol work in treating anemia in patients with myelofibrosis. Ruxolitinib phosphate and danazol may cause the body to make more red blood cells. They are used to treat anemia in patients with myelofibrosis.

Provided treatments

  • Drug: ruxolitinib phosphate
  • Drug: danazol
  • Other: quality-of-life assessment
  • Other: questionnaire administration
Tris trial is registered with FDA with number: NCT01732445. The sponsor of the trial is Mayo Clinic and it is looking for 14 volunteers for the current phase.
Official trial title:
A Phase 2 Pilot Trial of Ruxolitinib Combined With Danazol for Patients With Primary Myelofibrosis (MF), Post Essential Thrombocythemia-Myelofibrosis (Post ET) and Post Polycythemia Vera Myelofibrosis (PV MF) Suffering From Anemia